Live chimeric and inactivated japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus

Journal of Virology

Volumn 83, Issue 6, 2009, Pages 2436-2445

  Lobigs, Mario ^a   Larena, Maximilian ^a   Alsharifi, Mohammed ^a,b   Lee, Eva ^a   Pavy, Megan ^a  

^a Biology and Environment   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; INTERFERON; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIVIRAL ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENCEPHALITIS; FEMALE; FLAVIVIRUS; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; JAPANESE ENCEPHALITIS VIRUS; MALE; MOUSE; MURRAY VALLEY ENCEPHALITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; WEST NILE FLAVIVIRUS; ANIMAL; BLOOD; C57BL MOUSE; CROSS REACTION; EPIDEMIC ENCEPHALITIS; HUMAN; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MOUSE MUTANT; SURVIVAL; TIME;

JAPANESE ENCEPHALITIS VIRUS; MURRAY VALLEY ENCEPHALITIS VIRUS; MUS; WEST NILE VIRUS;

ANIMALS; ANTIBODIES, VIRAL; CROSS REACTIONS; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS VIRUS, MURRAY VALLEY; ENCEPHALITIS, ARBOVIRUS; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SURVIVAL ANALYSIS; TIME FACTORS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 62749205805     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02273-08     Document Type: Article

References (53)

1. Barrett, A. T., and E. A. Gould. 1986. Antibody-mediated early death in vivo after infection with yellow fever virus. J. Gen. Virol. 67:2539-2542.
2. Beasley, D. W., P. Lewthwaite, and T. Solomon. 2008. Current use and development of vaccines for Japanese encephalitis. Expert Opin. Biol. Ther. 8:95-106.
3. Broom, A. K., M. J. Wallace, J. S. Mackenzie, D. W. Smith, and R. A. Hall. 2000. Immunization with gamma globulin of Murray Valley encephalitis virus and with an inactivated Japanese encephalitis virus vaccine as prophylaxis against Australian encephalitis: evaluation in a mouse model. J. Med. Virol. 61:259-265.
4. Burke, D. S, and T. P. Monath. 2001. Flaviviruses, p. 1043-1126. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
5. Clark, D. C., M. Lobigs, E. Lee, M. J. Howard, K. Clark, B. J. Blitvich, and R. A. Hall. 2007. In situ reactions of monoclonal antibodies with a viable mutant of Murray Valley encephalitis virus reveal an absence of dimeric NS1 protein. J. Gen. Virol. 88:1175-1183.
6. Colombage, G., R. Hall, M. Pavy, and M. Lobigs. 1998. DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 250:151-163.
7. Douglas, M. W., D. P. Stephens, J. N. Burrow, N. M. Anstey, K. Talbot, and B. J. Currie. 2007. Murray Valley encephalitis in an adult traveller complicated by long-term flaccid paralysis: case report and review of the literature. Trans. R. Soc. Trop. Med. Hyg. 101:284-288.
8. Fang, Y., and W. K. Reisen. 2006. Previous infection with West Nile or St. Louis encephalitis viruses provides cross protection during reinfection in house finches. Am. J. Trop. Med. Hyg. 75:480-485.
9. Gould, E. A., and A. Buckley. 1989. Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence. J. Gen. Virol. 70:1605-1608.
10. Goverdhan, M. K., A. B. Kulkarni, A. K. Gupta, C. D. Tupe, and J. J. Rodrigues. 1992. Two-way cross-protection between West Nile and Japanese encephalitis viruses in bonnet macaques. Acta Virol. 36:277-283.
11. Guirakhoo, F., J. Arroyo, K. V. Pugachev, C. Miller, Z. X. Zhang, R. Weltzin, K. Georgakopoulos, J. Catalan, S. Ocran, K. Soike, M. Ratterree, and T. P. Monath. 2001. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol. 75:7290-7304.
12. Guirakhoo, F., Z. X. Zhang, T. J. Chambers, S. Delagrave, J. Arroyo, A. D. Barrett, and T. P. Monath. 1999. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257:363-372.
13. Hall, R. A., T. N. H. Brand, M. Lobigs, M. Y. Sangster, M. J. Howard, and J. S. Mackenzie. 1996. Protective immune responses to the E and NS1 proteins of Murray Valley encephalitis virus in hybrids of flavivirus-resistant mice. J. Gen. Virol. 77:1287-1294.
14. Halstead, S. B. 1982. Immune enhancement of viral infection. Prog. Allergy 31:301-364.
15. Halstead, S. B. 2003. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60:421-467.
16. Halstead, S. B., and T. F. Tsai. 2004. Japanese encephalitis vaccines, p. 919-958. In S. A. Plotkin and W. A. Orenstein (ed.), Vaccines, 4th ed. Saunders, Philadelphia, PA.
17. Hammon, W. M., and G. E. Sather. 1956. Immunity of hamsters to West Nile and Murray Valley viruses following immunization with St. Louis and Japanese B. Proc. Soc Exp. Biol. Med. 91:521-524.
18. Hanna, J. N., S. A. Ritchie, D. A. Phillips, J. M. Lee, S. L. Hills, A. F. van den Hurk, A. T. Pyke, C. A. Johansen, and J. S. Mackenzie. 1999. Japanese encephalitis in north Queensland, Australia, 1998. Med. J. Aust. 170:533-536.
19. Hanna, J. N, S. A. Ritchie, D. A. Phillips, J. Shield, M. C. Bailey, J. S. Mackenzie, M. Poidinger, B. J. McCall, and P. J. Mills. 1996. An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. Med. J. Aust. 165:256-260.
20. Hawkes, R. A. 1964. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust. J. Exp. Biol. Med. Sci. 42:465-482.
21. Hoke, C. H., A. Nisalak, N. Sangawhipa, S. Jatanasen, T. Laorakapongse, B. L. Innis, S. Kotchasenee, J. B. Gingrich, J. Latendresse, K. Fukai, et al. 1988. Protection against Japanese encephalitis by inactivated vaccines. N. Engl. J. Med. 319:608-614.
22. Hombach, J., T. Solomon, I. Kurane, J. Jacobson, and D. Wood. 2005. Report on a W. H. O.consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 23:5205-5211.
23. Kanesa-Thasan, N., J. R. Putnak, J. A Mangiafico, J. E. Saluzzo, and G. V. Ludwig. 2002. Absence of protective neutralizing antibodies to West Nile virus in subjects following vaccination with Japanese encephalitis or dengue vaccines. Am. J. Trop. Med. Hyg. 66:115-116.
24. Konishi, E., and T. Suzuki. 2002. Ratios of subclinical to clinical Japanese encephalitis (JE) virus infections in vaccinated populations: evaluation of an inactivated JE vaccine by comparing the ratios with those in unvaccinated populations. Vaccine 21:98-107.
25. Lee, E., R. A. Hall, and M. Lobigs. 2004. Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses. J. Virol. 78:8271-8280.
26. Lee, E., and M. Lobigs. 2002. Mechanism of virulence attenuation of GAG-binding variants of Japanese encephalitis and Murray Valley encephalitis viruses. J. Virol. 76:4901-4911.
27. Licon Luna, R. M., E. Lee, A. Müllbacher, R. V. Blanden, R. Langman, and M. Lobigs. 2002. Lack of both Fas ligand and perform protects from flavi-virus-mediated encephalitis in mice. J. Virol. 76:3202-3211.
28. Lobigs, M, A. Mullbacher, Y. Wang, M. Pavy, and E. Lee. 2003. Role of type I and type II interferon responses in recovery from infection with an en-cephalitic flavivirus. J. Gen. Virol. 84:567-572.
29. Lobigs, M., M. Pavy, and R. A. Hall. 2003. Cross-protective and infection-enhancing immunity in mice vaccinated against flaviviruses belonging to the Japanese encephalitis virus serocomplex. Vaccine 21:1572-1579.
30. Mackenzie, J. S, M. D. Lindsay, R. J. Coelen, A. K. Broom, R. A. Hall, and D. W. Smith. 1994. Arboviruses causing human disease in the Australasian zoogeographic region. Arch. Virol. 136:447-467.
31. Mackenzie, J. S, D. W. Smith, A. K. Broom, and M. R. Bucens. 1993. Australian encephalitis in Western Australia, 1978-1991. Med. J. Aust. 158:591-595.
32. Marshall, I. D. 1988. Murray Valley and Kunjin encephalitis, p. 151-189. In T. P. Monath (ed.), The arboviruses: epidemiology and ecology, vol. III. CRC Press, Inc., Boca Raton, FL.
33. Monath, T. P. 2002. Jennerian vaccination against West Nile virus. Am. J. Trop. Med. Hyg. 66:113-114.
34. Monath, T. P. 2002. Japanese encephalitis vaccines: current vaccines and future prospects. Curr. Top. Microbiol. Immunol. 267:105-138.
35. Monath, T. P., F. Guirakhoo, R. Nichols, S. Yoksan, R. Schrader, C. Murphy, P. Blum, S. Woodward, K. McCarthy, D. Mathis, C. Johnson, and P. Bedford. 2003. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis. 188:1213-1230.
36. Monath, T. P., I. Levenbook, K. Soike, Z. X. Zhang, M. Ratterree, K. Draper, A. D. Barrett, R. Nichols, R. Weltzin, J. Arroyo, and F. Guirakhoo. 2000. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J. Virol. 74:1742-1751.
37. Monath, T. P., K. McCarthy, P. Bedford, C. T. Johnson, R. Nichols, S. Yoksan, R. Marchesani, M. Knauber, K. H. Wells, J. Arroyo, and F. Guirakhoo. 2002. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20:1004-1018.
38. Müller, U., U. Steinhoff, L. F. Reis, S. Hemmi, J. Pavlovic, R. M. Zinkernagel, and M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264:1918-1921.
39. Peiris, J. S., and J. S. Porterfield. 1982. Antibody-dependent plaque enhancement: its antigenic specificity in relation to Togaviridae. J. Gen. Virol. 58:291-296.
40. Querec, T., S. Bennouna, S. Alkan, Y. Laouar, K. Gorden, R. Flavell, S. Akira, R. Ahmed, and B. Pulendran. 2006. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203:413-424.
41. Ritchie, S. A., D. Phillips, A. Broom, J. Mackenzie, M. Poidinger, and A. van den Hurk. 1997. Isolation of Japanese encephalitis virus from Culex annulirostris in Australia. Am. J. Trop. Med. Hyg. 56:80-84.
42. Russell, R. C., and D. E. Dwyer. 2000. Arboviruses associated with human disease in Australia. Microbes Infect. 2:1693-1704.
43. Samuel, M. A., and M. S. Diamond. 2005. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J. Virol. 79:13350-13361.
44. Shrestha, B., T. Ng, H. J. Chu, M. Noll, and M. S. Diamond. 2008. The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus. Vaccine 26:2020-2033.
45. Shu, P. Y., L. K. Chen, S. F. Chang, Y. Y. Yueh, L. Chow, L. J. Chien, C. Chin, T. H. Lin, and J. H. Huang. 2001. Antibody to the nonstructural protein NS1 of Japanese encephalitis virus: potential application of mAb-based indirect ELISA to differentiate infection from vaccination. Vaccine 19:1753-1763.
46. Stich, A., S. Gunther, C. Drosten, P. Emmerich, D. E. Dwyer, L. Hueston, W. Hetzel, A. Kirschner, and K. Fleischer. 2003. Clinical and laboratory findings on the first imported case of Murray Valley encephalitis in Europe. Clin. Infect. Dis. 37:el9-21.
47. Takasaki, T., S. Yabe, R. Nerome, M. Ito, K. Yamada, and I. Kurane. 2003. Partial protective effect of inactivated Japanese encephalitis vaccine on lethal West Nile virus infection in mice. Vaccine 21:4514-4518.
48. Tesh, R. B., A. P. Travassos da Rosa, H. Guzman, T. P. Araujo, and S. Y. Xiao. 2002. Immunization with heterologous flaviviruses protective against fatal West Nile encephalitis. Emerg. Infect. Dis. 8:245-251.
49. van den Broek, M. F., U. Muller, S. Huang, M. Aguet, and R. M. Zinker-nagel. 1995. Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J. Virol. 69:4792-4796.
50. Wallace, M. J., D. W. Smith, A. K. Broom, J. S. Mackenzie, R. A. Hall, G. R. Shellam, and P. C. McMinn. 2003. Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice. J. Gen. Virol. 84:1723-1728.
51. + T cells mediate recovery and immunopathology in West Nile virus encephalitis. J. Virol. 77:13323-13334.
52. Williams, D. T., P. W. Daniels, R. A. Lunt, L. F. Wang, K. M. Newberry, and J. S. Mackenzie. 2001. Experimental infections of pigs with Japanese encephalitis virus and closely related Australian flaviviruses. Am. J. Trop. Med. Hyg. 65:379-387.
53. Yamshchikov, G., V. Borisevich, C. W. Kwok, R. Nistler, J. Kohlmeier, A. Seregin, E. Chaporgina, S. Benedict, and V. Yamshchikov. 2005. The suitability of yellow fever and Japanese encephalitis vaccines for immunization against West Nile virus. Vaccine 23:4785-4792.